United States securities and exchange commission logo





                             August 23, 2023

       Juan Fernandez Pascual
       Chief Executive Officer, Secretary and Director
       Aimei Health Technology Co., Ltd.
       10 East 53rd Street, Suite 3001
       New York, NY 10022

                                                        Re: Aimei Health
Technology Co., Ltd.
                                                            Amendment No. 2 to
Registration Statement on Form S-1
                                                            Filed August 17,
2023
                                                            File No. 333-272230

       Dear Juan Fernandez Pascual:

             We have reviewed your amended registration statement and have the
following
       comments. In some of our comments, we may ask you to provide us with
information so we
       may better understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comments apply to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to these comments, we may have additional comments.
Unless we note
       otherwise, our references to prior comments are to comments in our
August 7, 2023 letter.

       Amendment No. 2 to Registration Statement on Form S-1 filed August 17,
2023

       If we seek shareholder approval of our business combination . . ., page
29

   1.                                                   We note the revisions
you made in response to prior comment 2. Please revise the
                                                        disclosure here and on
page 21 to explain how the purchase of shares by the sponsor or its
                                                        affiliates from public
shareholders in connection with the approval of the business
                                                        combination may
"influence a vote" if you intend that the sponsor and its affiliates will
                                                        represent that they
will not vote in favor of approving the business combination, or
                                                        remove this reference.
 Juan Fernandez Pascual
FirstName LastNameJuan
Aimei Health Technology Fernandez
                         Co., Ltd. Pascual
Comapany
August 23, NameAimei
           2023        Health Technology Co., Ltd.
August
Page 2 23, 2023 Page 2
FirstName LastName
Certain Relationships and Related Party Transactions, page 111

2.       We note that you have removed disclosure regarding your relationship
with ARC Group
         Limited from this section. However, we also note that the public
website for ARC Group
         indicates that an individual named Julianne Huh is a "strategic
partner" to ARC Group.
         The website also indicates that ARC has a vice president named Ulrich
Karlsen. If either
         of these individuals also serve as independent directors of Aimei,
please disclose this
         relationship and the agreement with ARC Group in this section and in
the biographical
         information for each individual, and file the agreement as an exhibit
to the registration
         statement.
Enforcement of Civil Liabilities in Hong Kong and China, page 121

3.       We note your response to prior comment 5 that Ms. Lin Bao's residence
in the PRC is
         disclosed in her biography on page 103. However, as this information
is directly relevant
         to the disclosure regarding the enforcement of civil liabilities in
China, please include it in
         the context of this discussion as well, as requested in our prior
comment.
Item 16. Exhibits and Financial Statement Schedule
Exhibit 23.1, page 146

4.       In your next amendment, please provide an updated consent from your
independent
         registered public accounting firm.
General

5.       We note your response to prior comment 6 and we reissue it in part.
Please include
         disclosure addressing the impact that PRC law or regulation may have
on the cash flows
         associated with a business combination in relation to shareholder
redemption rights.
       You may contact Mark Rakip at 202-551-3573 or Wilson Lee at 202-551-3468
if you
have questions regarding comments on the financial statements and related
matters. Please
contact Ronald (Ron) E. Alper at 202-551-3329 or Pam Long at 202-551-3765 with
any other
questions.



                                                                 Sincerely,

                                                                 Division of
Corporation Finance
                                                                 Office of Real
Estate & Construction
cc:      Andrei Sirabionian